Sharpless Calls For A Nimble, Flexible, More Efficient US FDA
In his first speech to an outside group, Sharpless strikes a collaborative tone, saying he expects to listen to the advice of the FDA bar, as well as his own experts.
You may also be interested in...
The MD Anderson Cancer Center administrator's lack of significant government administration experience may inspire questions during the confirmation process.
Acting commissioner is entering the usual learning curve for new leaders of the agency. It’s a reminder of how unusual it was to skip that step under his predecessor.
Like ANDA evaluations, US FDA plans to use the word assessment to describe them for NDAs and BLAs.